(CercleFinance.com) – Jefferies confirms its advice to buy on the stock with a price target of $350 while Leqembi has received full approval from the FDA (widely expected by the stock market according to the analyst).
Leqembi is the first and only approved treatment that has been shown to reduce the rate of disease progression and slow cognitive and functional decline in adults with Alzheimer’s disease, according to the Biogen group.
“We estimate Leqembi end-user sales of $30 million for 2023 and $298 million for 2024 (lower than forecast by $45 million/$408 million, respectively),” the analysts said.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
